BioNTech SE (ETR:22UA)

Market Cap	21.42B
Revenue (ttm)	3.15B
Net Income (ttm)	-571.60M
Shares Out	n/a
EPS (ttm)	-2.38
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	715
Average Volume	24,761
Open	89.85
Previous Close	89.85
Day's Range	87.00 - 89.85
52-Week Range	73.15 - 124.90
Beta	1.46
RSI	43.51
Earnings Date	Nov 3, 2025

About BioNTech SE

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in ph...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 6,772
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: 22UA